Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock

Stifel analysts reaffirmed their Buy rating on Phathom Pharmaceuticals (PHAT) with a $28 price target following the FDA's grant of 10-year exclusivity for Voquezna tablets, extending market protection until 2032. The decision is expected to help the stock recover from a recent decline driven by uncertainty surrounding the exclusivity period, with analysts anticipating the stock to reflect the strong launch of Voquezna. While H.C. Wainwright lowered its price target to $20 from $28, they also maintained a Buy rating, and InvestingPro data forecasts strong sales growth potential with revenue expected to nearly double this year.

Analysis

Phathom Pharmaceuticals (NASDAQ: PHAT) has secured a critical 10-year market exclusivity period for its Voquezna tablets from the U.S. Food and Drug Administration, extending protection until 2032 and aligning with existing Voquezna Paks. This development, following a citizen's petition, addresses a key uncertainty that contributed to the stock's decline from highs around $19 in September 2024 and a near 48% loss over the past six months. Stifel analysts maintained their Buy rating and $28.00 price target, anticipating share price recovery driven by Voquezna's strong launch and demand, noting their valuation already factored in this extended exclusivity. Further bolstering this outlook, Phathom reported better-than-expected first-quarter 2025 financial results, with earnings per share of -1.07 USD and revenue of 28.5 million USD, surpassing forecasts. InvestingPro data also signals strong sales growth, with revenue projected to nearly double this year. While H.C. Wainwright lowered its price target to $20 from $28, it reiterated a Buy rating, citing Phathom's strategic commercial shift towards gastrointestinal specialists and primary care to achieve profitability by 2026. Despite a recent 10.35% weekly gain, the company must still navigate market competition and the broader regulatory environment.

Key Decisions for Investors

• Consider the enhanced outlook for Phathom Pharmaceuticals following the FDA's 10-year exclusivity grant for Voquezna, which mitigates a key risk and supports analyst expectations for share price appreciation towards targets ranging from $20 to $28.
• Evaluate Phathom's execution on its refocused commercial strategy targeting specialist channels and its trajectory towards achieving profitability by 2026, as these are crucial for sustained value creation.
• Acknowledge the stock's significant recent volatility and the competitive landscape, suggesting a thorough risk assessment, even with positive catalysts like strong Q1 2025 earnings and projected robust revenue growth.